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Abstract 
Aims: 
The aim of this present study was to investigate the changes of peripheral sensory nerve 
excitability produced by propofol. 
 
Main methods: In a recently described in vitro model of rodent saphenous nerve we used the 
technique of threshold tracking (QTRAC®) to measure changes of axonal nerve excitability of 
Aβ-fibres caused by propofol. Concentrations of 10 μMol, 100 μMol and 1000 μMol were 
tested. Latency, peak response, strength-duration time constant (τSD) and recovery cycle of 
the sensory neuronal action potential (SNAP) were recorded. 
 
Key findings: Our results have shown that propofol decreases nerve excitability of rat primary 
sensory afferents in vitro. Latency increased with increasing concentrations (0 µMol: 0.96 ± 
0.07 ms; 1000 µMol 1.10 ± 0.06 ms, P<0.01). Also, propofol prolonged the relative refractory 
period (0 µMol: 1.79 ± 1.13 ms; 100 µMol: 2.53 ± 1.38 ms, P<0.01), and reduced 
superexcitability (0 µMol: -14.0 ± 4.0%; 100 µMol: - 9.5 ± 5.5 %) and subexcitability (0 µMol: 7.5 
± 1.2 %; 1000 µMol: 3.6 ± 1.2) significantly during the recovery cycle (P<0.01). 
 
Significance: Our results have shown that propofol decreases nerve excitability of primary 
sensory afferents. The technique of threshold tracking revealed that axonal voltage-gated ion 
channels are significantly affected by propofol and therefore might be at least partially 
responsible for earlier described analgesic effects. 
 
Key words:  propofol; nerve excitability; sensory afferents, threshold tracking 
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Introduction 
A recent report described short-lasting analgesic properties of propofol during its administration 
in a human pain model (Bandschapp et al., 2010). The mechanisms behind this effect, 
however, remain obscure. In theory, modulation of the nociceptive signalling by propofol can 
take place in both, the peripheral and central nervous system. As an effective general 
anesthetic propofol is acting on the transmission of action potentials on neuronal synapses in 
the central nervous system (CNS). The primary target of propofol is the GABAA receptor which 
is abundantly expressed in the CNS. But propofol also activates transient receptor potential 
(TRP) receptors TRPA1 and TRPV1 on nociceptors and may lead to a pain sensation at high 
concentrations (Fischer et al., 2010; Picard and Tramer, 2000).  Previous studies have shown 
that propofol also acts on voltage-gated ion channels involved in the excitability of neuronal and 
muscular cell membranes even at systemic concentrations reached during anesthesia 
(Haeseler et al., 2001). Possible mechanisms include shortening of the opening of voltage-
gated sodium channels and a prolonging of their steady-state inactivation in the CNS (Frenkel 
and Urban, 1991). Additionally, propofol shifts the inactivation of sodium channels towards 
more hyperpolarizing potentials, resulting in suppression of excitability (Rehberg and Duch, 
1999). Although these results are not fully conclusive since they describe effects on different 
subtypes of voltage-gated sodium channels either in skeletal muscle (NaV1.4), or in the central 
nervous system (NaV1.1, NaV1.2, NaV1.3), they also suggest a possible role of the subtype 
NaV1.6 in myelinated nerve fibers (Kakinohana et al., 2002; Dueck et al., 2003). The necessary 
concentrations to elicit these effects in the afore mentioned studies were all below 100 μM and 
therefore close to the therapeutic range in a setting of general anesthesia (Kazama et al., 
1997). A recent clinical investigation showed that excitability of peripheral sensory Aβ-afferents 
which mainly involves subtype NaV1.6 is altered during the induction of anesthesia with propofol 
(Maurer et al., 2010). In this study, a direct action of propofol on peripheral excitability was 
proposed, however an interfering temperature effect could not be excluded. 
The purpose of this present study was to investigate a direct effect of propofol on axonal nerve 
excitability in a setting where a possible temperature effect can be controlled. We used the 
technique of threshold tracking in an in- vitro model of rodent saphenous nerve which simulates 
accurately the changes which occur in human models in a qualitative manner (Maurer et al., 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
  4   
    
2007). This technique provides information about axonal function of peripheral nerves in 
contrast to routine nerve conduction studies which is measuring amplitude and velocity only.   
 
Materials and Methods  
Ethics: All the animal work was done in accordance to the Swiss Animal Protection Act 2008 
and after approval of the Health Department of the Canton of Zurich, Switzerland, reg. nr. 
217/2007. A total of 13 nerves of 13 adult female Wistar rats were used in the investigation. 
The animals were killed by 100 % CO2. The saphenous nerve and its innervated skin were 
excised from hind limbs and kept corium-side up in an organ bath (Fig. 1). The preparation was 
superfused by synthetic interstitial fluid (SIF, in mmol/l): 124 NaCl, 3.5 KCl, 0.7 Mg(H2O)7, 1.65 
NaH2PO4, 2 CaCl2, 9.6 sodium gluconate, 5.55 glucose and 2.9 sucrose. The pH of the SIF 
was maintained at 7.40 by continually gassing with a mix of 95% oxygen and 5% carbon 
dioxide (carbogen). The temperature of the bath was maintained at 32°C which corresponds to 
a physiological temperature of a cutaneous nerve. The nerve’s proximal end was desheathed 
1mm and placed in a separate chamber isolated by silicone oil. Recordings were obtained with 
gold wire electrodes where the cathode served as an active electrode and the anode as 
reference electrode positioned nearby in the SIF. Generated action potentials were recorded 
with an isolated bio-amplifier (ISO-80, World Precision Instruments, Hertfordshire, UK). 
Recordings were started only after the nerve has been in the organ bath for an equilibrating 
period of 2 hours. 
A 1 % propofol stock solution (10mg/ml; Disoprivan®; AstraZeneca AG, 6301 Zug, Switzerland) 
was dissolved in SIF to make up the working solutions of different concentrations (e.g. 0.089 
mg/l = 500 μM; MW = 178.2).  To separate the effects of the active component propofol and the 
vehicle intralipid (Sojae oleum 100 mg/ml, 1.2% purified egg phospholipid, 2.25% of glycerol) 
we tested the effect of vehicle alone (Intralipid® 10%; Fresenius Kabi, 6371 Stans, Switzerland). 
In these preliminary experiments (n = 5) intralipid (100 mg/ml) was dissolved in SIF analogously 
in a concentration equivalent to the tested propofol. The nerve was cut, desheathed over 3 mm 
and stimulated with a silver wire within a suction electrode. During continuous recording of 
control threshold and superexcitability (s. paragraph below, ‘threshold tracking’), intralipid alone 
was first washed in for 15 minutes. Subsequently, after a washout of 10 minutes 500 μM 
propofol was washed in for 15 minutes, followed by a washout period.  
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We applied propofol using concentrations between 10μM and 1 mMol. The recording setting 
was changed in the following manner: We left the nerve attached to the skin and stimulated 
using an Ag/AgCl electrode with an uninsulated tip diameter of 2 mm (EPO5, World Precision 
Instruments, Hertfordshire, UK) with the cathode positioned within the ring and the anode put 2-
3 cm outside the ring in the organ bath (Fig. 1). In contrast to the stimulation with suction 
electrodes, this arrangement allows better to perform excitability measurements with stimulation 
protocols which include polarizing conditioning stimuli. Different concentrations of propofol (0 
μMol 10 μMol, 100 μMol and 1000 μMol) were applied within the ring using a circulating system 
which was independent of the rest of the organ bath. Analogously to the circulation system of 
the organ bath, the SIF containing the active component was continually gassed with carbogen 
and also maintained at 32 ˚C. Cumulative concentration-response studies were conducted on 
each nerve preparation. Each concentration was washed in for at least 40 minutes in order to 
reach a steady state. During the actual recording of the excitability parameters the content of 
the ring was replaced by silicone oil (32 ˚C) containing the same concentration of propofol as 
the SIF washed in immediately before.  
For both sets of experiments, the wave form of the stimulus was generated by the software 
QTRAC© (Institute of Neurology, University College London, UK) and converted to current 
using an isolated linear constant current stimulator (Linear Stimulus Isolator A395, World 
Precision Instruments, Hertfordshire, UK). Generated action potentials were recorded with an 
isolated bio-amplifier (ISO-80, World Precision Instruments, Hertfordshire, UK) from the 
proximal nerve’s ending using the following settings: low pass filter: 2000 Hz; high pass filter: 1 
Hz; gain 1000x. Data were then digitized by a data acquisition unit (CED micro1401 MK II, 
Cambridge Electronic Design Ltd, Cambridge CB4 0FE, UK) using a sampling rate of 10 kHz. 
All measurements with propofol were carried out in concentrations of ascending order. Upon 
completion, the recording site within the ring was washed out with SIF alone for 90 minutes and 
followed by a final recording.  
Threshold tracking 
We used a computer-assisted threshold tracking program (QTRAC© Institute of Neurology, 
Queen Square, London, UK) to investigate the excitability parameters and ion conductances in 
myelinated sensory axons in peripheral nerves (Maurer et al., 2010; Bostock et al., 1998; 
Z'graggen and Bostock, 2008). The recording protocols allow to measure specific 
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electrophysiological parameters. Detail of the protocols, how the measurements were plotted 
and interpreted are extensively described in previous publications (Maurer et al., 2010; Maurer 
et al., 2007; Bostock et al., 1998). In the following, only a short description of the recording 
protocol is given. Throughout the entire recording protocol, a stimulus frequency of 1 Hz was 
chosen. The stimulus strength was adjusted in a feed-back controlled manner for different test 
paradigms to produce the target response using proportional tracking (Bostock and Rothwell, 
1997). First, a stimulus-response curve was recorded by increasing the stimulus current until a 
maximum sensory nerve action potential (SNAP) was obtained. 40 % of the maximal response 
was defined as the target response. The current used to reach this target response is referred 
as “threshold”. Between 40% and 50% of the maximal response size, small changes in stimulus 
strength evoke major changes in size of the action potential because the slope of the stimulus-
response curve is steepest (Maurer et al., 2007). Second, to record the strength duration 
relationship, stimuli of different widths were applied and the current required to reach the 
“threshold” was tracked. Third, the recovery of excitability following a single supramaximal 
stimulus was measured. Therefore, the nerve was stimulated with three different alternating 
stimulation patterns: (i) control test stimuli tracking the threshold current, (ii) supramaximal 
conditioning stimuli (140 % of the current needed for a maximal response), (iii) supramaximal 
conditioning stimuli followed by a test stimulus at variable interstimulus intervals. The effective 
size of the test action potential after the combined stimulus (iii) was calculated by subtracting (ii) 
from (iii). Excitability changes were recorded at different conditioning-test intervals between 200 
ms and 2 ms in an approximately geometrical sequence. The threshold change was normalized 
and plotted against the interstimulus interval (fig. 3 A). This method of plotting easily identifies 
the different phases of the excitability changes of a nerve after a supramaximal stimulus (e.g. 
relative refractory period, superexcitable period, subexcitable period, s. fig. 3 A) as described 
by Raymond (Raymond, 1979). Zero on the y-axis represents the control threshold.  
Statistical Analysis 
All values are given as means ± SD except in figures 2C, 3B and 4C, where SEs were used. To 
analyse data we used the software QtracP (Version 3/4/2009, ® Institute of Neurology, 
University College London, UK). Data were tested for a normal distribution with Lillefor’s test for 
normality. In the preliminary vehicle experiment we used a paired t- test to compare excitability 
changes between control, intralipid and propofol. A Bonferroni correction was performed to 
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address multiple comparisons for the same variable. Concentration-response data were 
depicted as semilogarithmic graphs, with data fitted with regression analysis for the best fit. In 
the main experiments we used repeated measures ANOVA with Bonferroni corrections to 
compare the changes of excitability parameters at different propofol concentrations. P-values < 
0.05 were considered statistically significant.  
 
 
Results 
Our results showed a reduction of excitability parameters in sensory nerve afferents with 
increasing concentration of propofol. 
The vehicle intralipid alone did not cause any excitability changes 
In the first set of experiments with we tested the hypothesis that commercially available 
propofol affects peripheral nerve excitability and that this effect was caused by the active 
component propofol. We found no significant effect of intralipid, the vehicle of propofol, on 
threshold (100.5 ± 8 %, P=0.73), superexcitability (-44 ± 1 %, P=0.57) or peak amplitude 
response (98 ± 1 %, P=0.52) measurements (Fig. 2). In contrast, a significant change in 
threshold (131 ± 18 %, P<0.05) and superexcitability (-39 ± 3 %, P<0.05) was immediately 
observed during the infusion of an equivalent concentration of 500 µMol propofol. Although the 
peak amplitude decreased (90 ± 7 %) during this infusion, this change was not statistically 
significant (P=0.06). It is  
Excitability changes caused by propofol 
An overview of the excitability changes in the second set of experiments are given in Table 1. 
All the changes in excitability parameters were only partially reversible during the wash-out 
phase of propofol for reasons that are discussed in the discussion section. The stimulus-
response curve shifted towards smaller responses (on the y-axis) with increasing 
concentrations (Fig. 3 A). Therefore the size of the maximal SNAP (peak response) decreased 
with increasing concentration (0 µMol: 6.7 ± 2.0 mV; 1000 µMol: 3.7 ± 1.0 mV; P=0.09). The 
stimulus strength required to reach the peak did not change (no shift on the x-axis). 
Furthermore, propofol slowed conduction velocity: latency (measured from the start of the 
stimulus to the peak of the SNAP) increased significantly with increasing concentrations (0 
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µMol: 0.96 ± 0.07 ms; 1000 µMol 1.10 ± 0.06 ms; P<0.01; Fig. 3). Strength-duration time 
constant (τSD) steadily increased during the application of higher concentrations of p 
opofol (table 1). τSD reversed to the level of the control values after wash-out. However, this 
effect was statistically not significant. Rheobase remained similar for all measured 
concentrations including the wash-out (table 1). Much stronger effects on nerve excitability 
were observed during the recovery cycle (Fig. 4). Propofol prolonged the relative refractory 
period (RRP) with increasing concentrations (0 µMol: 1.79 ± 1.13 ms; 100 µMol: 2.53 ± 1.38 
ms; P<0.01). In parallel, the extent of the superexcitability decreased (0 µMol: -14.0 ± 4.0%; 
100 µMol: - 9.5 ± 5.5 %; P<0.01). At the highest concentration of 1000 µMol the nerve did not 
enter a superexcitable period at all. Therefore, the RRP could not be determined any longer. At 
this concentration, the current strength desired to reach the target size of the SNAP was higher 
than the control current during an interstimulus interval of ~ 100 ms. After the wash-out, the 
nerve was superexcitable again and accordingly, the RRP could be determined again. The 
maximum change of threshold during the subexcitable period decreased significantly with 
increasing propofol concentration (0 µMol: 7.5 ± 1.2 %, 1000 µMol: 3.6 ± 1.2 %; P<0.01).  
 
Discussion 
The current study showed that propofol modulates axonal nerve excitability of primary sensory 
afferents in a concentration-dependent way. The threshold tracking technique revealed an 
involvement of different voltage-gated ion channels. 
 
Slowing of conduction velocity and decrease in peak response imply a block of voltage-gated 
sodium channels 
In our experiments propofol produced a slowing of conduction velocity (calculated as 
conduction distance divided by latency). Theoretically, three main physiological mechanisms 
can account for this finding assuming the maintained integrity of the myelin sheath: (i) A 
decreased number of available voltage-gated sodium channels which are opened during an 
action potential along the axon. Either, they were in an inactive state or they were blocked by 
propofol. (ii): Kinetics of voltage gated ion channels was altered. This usually happens with a 
temperature change (Paintal, 1965).  In this study, temperature was maintained stable 
throughout the whole experiment, therefore we reject this possibility (iii): Repetitive stimulation 
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of nerve fibres at high frequencies generate an activity-dependent hyperpolarization 
intracellulary limited by differences in the resting membrane potential prior to activation 
(Bostock et al., 2003) or a differential effectiveness of the electrogenic sodium pump (Na+/K+-
ATPase) (Rang and Ritchie, 1968). In our experiments, the stimulation frequency of 1 Hz was 
too low to generate activity-dependent hyperpolarization. We therefore the must assume that 
the most probable explanation for the decrease of conduction velocity is a direct impact of 
propofol on voltage-gated sodium channels.  From previous studies we know that 
administration of systemic sodium channel blockers slows down conduction velocity at 
concentrations much lower than needed for conduction block (De Jong and Nace, 1968; Fink 
and Cairns, 1984; Lang et al., 2007). Furthermore, Aβ-fibers can be blocked at lower 
concentrations of sodium channel blockers as compared to small-diameter fibres (Fink and 
Cairns, 1984) and they manifest significantly more slowing of conduction velocity (Fink and 
Cairns, 1984; Gokin et al., 2001). In line with the interpretation that propofol blocked voltage-
gated sodium channels was the observation that the size of the maximal compound action 
potential decreased with increasing propofol concentration. Again, the most probable 
explanation is an intrinsic blocking of voltage-gated sodium channels. Blocking of sodium 
currents lead to a reduced size of peak response (Butterworth and Stricharzt, 1990) by three 
main mechanisms: (i) Individual fibres within the nerve show a differential slowing pattern 
leading to a flattening out of the compound action potential; (ii) Reduced availability of fibres by 
a complete conduction block or, (iii) changes in the amplitude of individual spikes (Fink and 
Cairns, 1984). Taken together these findings with previously published data produced in other 
models at similar propofol concentrations (Rehberg and Duch, 1999) we assume that propofol 
had the capacity to block axonal sodium channels which led to both, conduction velocity 
slowing and decrease in peak response. We can only speculate about which sodium 
conductances were blocked by propofol. One possibility is a direct block of transient sodium 
currents by a local anesthetic-like mechanism within the pore. An equally plausible variant 
would be that the axons were depolarized in the presence of propofol because persistent Na 
currents were blocked, leading to a depolarization of the axons and consequently to an 
inhibition of the number of channels available to deliver transient current.  
 
The recovery cycle reveals involvement of voltage-gated potassium channels  
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After a supramaximal stimulus a typical sequence of excitability changes of the axonal 
membrane takes place which is called ‘recovery cycle’. After being refractory axons first enter a 
superexcitable then a subexcitable period before excitability thresholds normalize again (Stys 
and Ashby, 1990). Underlying mechanisms are complex and involve mainly sodium 
conductances at short interstimulus intervals (Hodgkin and Huxley, 1952), and capacitive 
charging of the internode (Barrett and Barrett, 1982), periaxonal accumulation of potassium 
(Kocsis et al., 1983) and slow potassium conductances at longer interstimulus intervals (e.g. 
late subexcitability) (Stys and Waxman, 1994; Schwarz et al., 2006). 
Virtually all excitability parameters during the recovery cycle showed dose-dependent 
excitability changes. However, the changes were small and significant effects were only 
observed at higher concentrations. In general, the method of threshold tracking allows to 
attribute certain findings to functions of specific voltage-gated ion channels (e.g. sodium or 
potassium channels, (Burke et al., 2001)). On the other hand, the technique is often not specific 
enough and the measurements represent a combination of effects on different factors 
determining excitability. For example, the RRP is most sensitive to changes in persistent 
sodium conductances (Baker and Bostock, 1997). In our experiments, RRP increased in a 
dose-dependent manner. But equally or even more affected was the superexcitable period 
which is also dependent on changes of the resistance of paranodal membrane by voltage-
dependent effects on paranodal potassium channels (Burke et al., 2001).  At the highest 
propofol concentration, no superexcitability – and therefore no RRP – was measurable any 
longer. The induced changes resembled those described in depolarized nerves (Kiernan and 
Bostock, 2000). Their investigations showed that depolarizing currents induce an abolishment 
of superexcitability and late subexcitability. This differs from excitability changes caused by 
hypoxemia, where late subexcitability is not altered (Kiernan and Bostock, 2000). In our 
experiments, late subexcitability decreased only at higher concentrations of propofol. Since 
previous studies showed that late subexcitability can be specifically suppressed by blocking 
slow potassium currents (Schwarz et al., 2006) we may assume that propofol also affects these 
slow potassium currents.  
 
Limitation of informative value of threshold tracking techniques 
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Measurements of nerve excitability always reflect a combination of all the factors that determine 
the excitability of a nervous membrane. Therefore, the overall interpretation of the changes in 
excitability induced by difference concentration of propofol can not be explained separately to 
each parameters, but rather as a result together. The main determinant of course is the resting 
membrane potential of the axonal membrane which is dependent on ion-channels (voltage 
gated, ligand-gated) ion pumps and temperature (Goldman, 1943) but also on intra- and 
extracellular proteins, amino acids, pH etc. Whether we eventually measured a direct effect of 
propofol on voltage-gated ion channels or an indirect effect by affecting factors that alter resting 
membrane potential and, hence, the function of these channels remains uncertain. A simple 
and objective means of interpreting these nerve excitability recordings would be by matching 
them with a computer model (Bostock, 2006). However, to date such modelling only exists in 
human motor nerve which is difficult to compare with rodent sensory nerve.  
Another limitation was the method of drug application in our rodent model. Since the drug does 
not reach the nerve membrane via vasa nervorum the time constant of the effects cannot be 
compared to data obtained in human studies and we must assume that all the effects that we 
measured occurred with a certain time lag. In the preliminary experiments we used a different 
setup to separate effects of the active component propofol and the vehicle intralipid than for the 
main experiments. The nerve was (i) desheated and (ii) stimulated with a suction electrode. In 
this setup smaller stimulation currents were needed and smaller compound action potentials 
produced. We explained these phenomenons by a shortfall of fibres due to the mechanical 
impact of the suction electrode and the lacking neural sheet. This was the reason to use nerves 
with intact neural sheets for the main experiments.  With the neural sheet intact 40 minutes 
wash in time was required to reach a steady state, in comparison to 15 minutes using the 
desheathed experimental set-up. This suggests that the sheath surrounding the nerve acts to 
limit the wash-in of propofol to considerable extent. Similarly to the second set of experiments, 
only a partial washout was observed which also can be explained by the nerve sheath acting as 
a barrier and explains why the effect of propofol was not fully reversible in our experimental 
setup.  
 
Implications on pain perception of the excitability changes observed   
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
  12   
    
From clinical practice it is well known that propofol at high concentrations causes pain at the 
site of injection (Tan and Onsiong, 1998). Mechanisms proposed include the activation of 
nociceptors by acidic sensing ion channels (Klement and Arndt, 1991) or by an indirect action 
via the plasma kallikrein-kinin system (Scott et al., 1988). Recent reports suggest a major role 
for transient receptor potential (TRP) ion channels, especially TRPA1 (Matta et al., 2008;Lee et 
al., 2008). This effect is only local and occurring at high concentrations which has to be clearly 
differentiated of systemic effects at much lower concentrations. Propofol has an analgesic 
effect in subhypnotic concentrations (Hand et al., 2001; Bandschapp et al., 2010) and is able to 
suppress spinal sensitization (O'Connor and Abram, 1995) and interneuronal activity in cerebral 
cortex (Woodforth et al., 1999). However, the mechanisms underlying this analgesic effect 
remain unclear. A possible involvement of the peripheral nervous system has been discussed 
(Bandschapp et al., 2010) but no investigation so far was designed to look at the periphery. All 
the electrophysiological (clinical) investigations have so far considered the effect of general 
anaesthetics on afferent axons as negligible, since axons are not usually considered as neural 
targets for these agents (Raymond et al., 1991; Sloan and Jäntti, 2008). A recent investigation 
in pati ents with the same threshold tracking technique used in the present study revealed an 
effect on voltage-gated sodium channels in Aβ-afferents. But the measurements recorded were 
not conclusive about whether sodium currents were blocked or the kinetics of the sodium 
channels were altered by a minimal temperature increase at the stimulation site (Maurer et al., 
2010). 
In the peripheral nervous system, a well organized interaction of different subtypes of voltage-
gated ion channels defines the size, frequency and the speed of an action potential. Even a 
slight shift in membrane potential of a nerve membrane can lead to severely altered excitability 
properties, and thereby modulate the information conveyed to the central nervous system 
(Raymond et al., 1990; Amir et al., 1999). Along this line of argumentation the alteration of the 
membrane potential in the present study might be important enough to influence pain 
perception even at a peripheral level and be responsible – at least to some part – for an 
analgesic effect of low-dose propofol.  
 
Conclusions 
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This is the first investigation that has systematically studied the effect of propofol on axonal 
excitability of primary sensory afferents. Our data suggest that the main effect of propofol on 
myelinated peripheral sensory afferents was an overall decrease in excitability. We could show 
that propofol reduces nerve excitability in a concentration dependent manner. Based on the 
existing knowledge of the threshold tracking technique and the interpretation of the resulting 
data the changes observed could theoretically be explained by a significantly altered function of 
axonal voltage-gated sodium channels of Aβ-afferents. We therefore also assume that the 
analgesic effects described in previous studies could be caused at least partially in the 
peripheral nervous system.  
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Table 1 Summary of nerve excitability changes induced by propofol in vitro. 
Propofol concentration 0 µMol 10 µMol 100 µMol 1000 µMol P Wash-out 
Latency (ms) 0.96 ± 0.07 1.01 ± 0.09 
1.03 ± 
0.07 1.10 ± 0.06 <0.01 
1.07 ± 
0.07 
Peak (mV) 5.4 ± 2.0 3.7 ± 2.0 3.3 ± 2.4 3.0 ± 2.1 0.09 4.2 ± 2.2 
SDTC (ms) 0.12 ± 0.03 0.15 ± 0.08 
0.16 ± 
0.10 0.17 ± 0.06 0.23 
0.12 ± 
0.03 
Rheobase (mA) 0.34 ± 0.04 0.41 ± 0.10 
0.29 ± 
0.10 0.37 ± 0.06 0.72 
 0.38 ± 
0.07 
Superexcitability (%) -14 ± 4 - 13 ± 5 - 10 ± 6 n.a.* <0.01 - 8 ± 6 
Subexcitability (%) 8 ± 1 8 ± 3 6 ± 3 4 ± 1 <0.01 5 ± 2 
Relative Refractory Period 
(ms) 1.79 ± 1.13 1.93 ± 1.25 
2.53 ± 
1.38 n.a.* <0.01 
2.93 ± 
1.43 
Refractoriness at 2.0 ms (%) -7 ± 2 -1 ± 2 10 ± 3 45 ± 3 <0.01 11 ± 3 
 
All values are given as mean ± SD (n=13). A repeated measures ANOVA was used to 
compare changes of the measured parameters with increasing concentration of propofol. 
SDTC = strength-duration time constant. n.a.* = not applicable: At the highest 
concentration of propofol the nerve membrane did not enter the superexcitable period. 
Therefore, the relative refractory period and superexcitability were not measurable. 
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FIGURE CAPTIONS 
 
Figure 1. Experimental setup.  
The saphenous nerve of the rat was placed in synthetic interstial fluid (SIF) which 
was circulating in an organ bath. The nerve’s proximal ending was placed in a 
separate recording chamber and isolated from SIF by silicone oil. The temperature 
of the bath was maintained at 32°C and the SIF was constantly gassed with 95% 
oxygen and 5% carbon dioxide. A second circuit independent from the organ bath 
contained propofol dissolved in SIF. Within the compartment of the metal ring the 
nerve was exposed to propofol at different concentrations and also gassed 
continuously. 
 
Figure 2. Excitability changes caused by vehicle vs. propofol 
a. The graphically generated A-fiber compound action potentials (A-CAPs) 
represent the mean of three A-CAPs of each of the 5 investigated nerves (totally 
15 CAPs).  Dashed line represents A-CAP waveform during control (left) and 
washout period 1 (right). Solid line represents A-CAP waveform during 500 µMol 
intralipid (right) and equally diluted intralipid (left) infusion. No difference in 
waveform was found after intralipid infusion, but there was a decrease in peak 
amplitude and a slight slowing of latency (represented by a shift in waveform 
towards the right) during the infusion of propofol with the vehicle.  Arrows indicates 
the onset of electrical stimulation. b. Original recording showing continuous 
tracking of threshold and superexcitability (measured at an interstimulus interval of 
6.3ms) over time in response to 500 µMol propofol and equally diluted intralipid. 
Note the increase in threshold and decrease in superexcitability during propofol 
application. During the washout 2, threshold returned only partially towards pre-
propofol values. C. Average change in peak amplitude, threshold and 
superexcitability expressed as a percentage of the control values. Data are shown 
as mean ± SEM. (n = 5). 
 
Figure 3. Peak response and latency changes. 
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a. The stimulus-response curve shifted downwards on the y-axis with increasing 
propofol concentration, indicating a smaller response while the stimulus strength 
remained similar. b. Consequently, the peak response after a maximal stimulus 
decreased. The latency increased (hence, conduction velocity decreased) with 
increasing concentration of propofol. Error bars are SEM (n=13). 
 
Figure 4. Recovery cycle. 
a. After a supramaximal conditioning stimulus excitability changes were recorded 
at different conditioning-test intervals between 200 ms and 2 ms in an 
approximately geometrical sequence. The change of currents of the test stimuli to 
reach the threshold is plotted on the y-axis in a normalized way, whereby zero 
represents the unconditioned control threshold. Immediately after a supramaximal 
conditioning stimulus the nerve enters the refractory period. The refractory period 
ends as soon as the curve crosses the zero line for the first time below zero. 
Thereafter, the nerve enters a superexcitable period until it becomes subexcitable 
(second intersection of the curve with the zero line). Normal excitability is restored 
after 200 ms. The recovery cycle curve shifted to the right with increasing propofol 
concentrations. At the same time, superexcitability decreased and was completely 
abolished at the highest propofol concentration. Consequently, the relative 
refractory period could not be determined (no intersection with zero line). 
Subexcitability also decreased significantly. All those changes restored only 
partially after wash-out (dashed line). b. Concentration-response curves showed a 
strong second-order correlation for superexcitability, relative refractory period and 
subexcitability. Error bars are SEM (n=13). * This parameter could not be 
determined (s. above). 
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